Data confirm 'the strengthening of the country's position as an increasingly attractive and competitive destination for conducting clinical trials in the European context'.
Infarmed approves 190 clinical trials in 2025 and cuts average decision time to 32 days
Friday, 16 January 2026RSS
Context & Explainers
Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde) is Portugal’s national regulator for medicines and health products that approves drugs, monitors safety and enforces rules on pricing and reimbursement. In 2025 it approved 928 new medicines — 79% were generics, 38 were designated essential and 236 were national products — which affects which medicines are available and how much they cost at pharmacies.
